HK
HKPD.US Cellyan Biotechnology Co., Ltd
- Market cap
- USD 3.99M
- P/E
- -
- P/B
- 0.42x
- ROE
- -53.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is HKPD.US undervalued?
Graham numberThe Graham number of Cellyan Biotechnology Co., Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cellyan Biotechnology Co., Ltd fundamental analysis
No fundamental analysis for Cellyan Biotechnology Co., Ltd yet.
Cellyan Biotechnology Co., Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch p…
Full company profileCellyan Biotechnology Co., Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cellyan Biotechnology Co., Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 12.6M | 16.7M | 20.3M | 13.4M | 25.2M |
| Gross Profit | 2.74M | 3.56M | 2.42M | 1.39M | 1.82M |
| Operating Income | 1.04M | 1.61M | 132K | -995K | -4.92M |
| EBITDA | 1.76M | 2.53M | 1.21M | -318K | -3.96M |
| Net Income | 998K | 1.33M | -27.1K | -1.14M | -5.16M |
| EPS | 1.81 | 3.61 | -0.05 | -0.97 | -2.87 |
| Balance Sheet | |||||
| Total Assets | 3.41M | 8.67M | 9.42M | 12.8M | 12.8M |
| Total Liabilities | 2.82M | 4.41M | 4.43M | 3.26M | 3.26M |
| Shareholders' Equity | 585K | 4.25M | 4.99M | 9.58M | 9.58M |
| Cash & Short-term Investments | 525K | 620K | 3.01M | 222K | 222K |
| Total Debt | 691K | 2.09M | 2.37M | 1.26M | 1.26M |
| Cash Flow | |||||
| Operating Cash Flow | 1.73M | -394K | 569K | -752K | -2.03M |
| Capital Expenditure | 118K | 88.0K | 155K | 35.5K | 148.00 |
| Free Cash Flow | 1.61M | -482K | 414K | -787K | -2.03M |
| Ratios | |||||
| ROE | 170.6% | 31.3% | -0.5% | -11.9% | -53.8% |
| ROA | 29.3% | 15.3% | -0.3% | -8.8% | -40.2% |
| Net Profit Margin | 7.9% | 8.0% | -0.1% | -8.5% | -20.5% |
| Debt to Equity | 1.18x | 0.49x | 0.48x | 0.13x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cellyan Biotechnology Co., Ltd dividends
Cellyan Biotechnology Co., Ltd has not paid dividends in the last 4 fiscal years.
Last stock split: 1:20 on Oct 26, 2026.
Who owns Cellyan Biotechnology Co., Ltd
- Insiders 17.34%
- Institutions 0.91%
- Public & others 81.75%
- Shares outstanding 2.11M
- Free float 817K
Top institutions holding HKPD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| StoneX Group Inc | 102K | 0.21% | +159.70% | Jun 2026 |
| Jane Street Group LLC | 49.1K | 0.10% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 41.8K | 0.08% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 38.9K | 0.08% | 0.00% | Jun 2026 |
| Clear Street Group Inc | 12.0K | 0.02% | 0.00% | Jun 2026 |
| UBS Group AG | 1.08K | 0.00% | +882.73% | Jun 2026 |
| Two Sigma Investments LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Cellyan Biotechnology Co., Ltd company profile
- Company name
- Cellyan Biotechnology Co., Ltd
- Ticker
- HKPD.US
- ISIN
- KYG6365B1041
- Exchange
- USA Stocks
- Listed since
- Jan 15, 2025
- Sector
- Healthcare
- Industry
- Air Freight & Logistics
- Employees
- 11
- Fiscal year end
- March
- Address
- Well Town Industrial Building, Yau Tong, Hong Kong, 999077
- Phone
- 852 2618 9289
- Website
- 9zt.hk
About Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products. The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
Cellyan Biotechnology Co., Ltd management
3- Mr. Chenyu LiangCEO & Director · born 2000
- Ms. Shu LiuChief Financial Officer · born 1996
- Mr. Zifeng WangChief Strategy Officer · born 1972